COMP <GO>
UTHR vs UNH // FREE CASH FLOW YIELD
United Therapeutics Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: UTHR 9
— UNH 5
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $596.13 (-0.43%) • MKT CAP: $25.68B
fcf-yield
4.09%
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
fcf-yield
6.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 88.57% | -0.67 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 11.47% | +8.63 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 16.5x | -3.98 | UTHR | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.09% | 6.47% | -2.38 | UNH | /fcf-yield <GO> |
| Operating Margin | 46.90% | 4.82% | +42.08 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 3.14% | +38.76 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 6.46% | +4.14 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 3.12 | +19.40 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 57.4 | +11.20 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | UTHR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 17.7x | +0.06 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.68B | $365.29B | -$339.61B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | UNH REV | UTHR GROSS % | UNH GROSS % | UTHR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $447.57B | 87.9% | 88.7% | $1.04B | $16.07B |
| FY 2024 | $2.88B | $400.28B | 89.2% | 88.3% | $1.08B | $20.70B |
| FY 2023 | $2.33B | $371.62B | — | 89.6% | $873.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
UNH // BETA 0.33